Skip to content
naulon
Not checkedNot checked for notices yet.

Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections

Raghuram Koganti, Tejabhiram Yadavalli, Deepak Shukla

Microorganisms · 2019

doi:10.3390/microorganisms7100429 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Herpes simplex virus type-1 (HSV-1) is a neurotropic, double-stranded DNA virus that can cause a wide variety of diseases, including many ocular pathologies. It is one of the leading causes of infectious blindness in the United States. Because of its ubiquitous nature and its potential to cause serious ocular maladies, there is a significant need for more effective antiviral therapies against ocular HSV-1. In this review, we discuss the lifecycle of HSV-1 as it pertains to corneal infections and the clinically approved as well as emerging treatments to combat HSV-1 infections. We also highlight some newly identified host targets for the antiviral drug development.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.